“…In a University of North Carolina Hospitals study of 105 patients, 3% and 5% of their reviewed cases received a ''major'' or a ''minor change'' status respectively, after weekly chart rounds [18]. Using the aforementioned RANZCR audit tool, 8 of 208 (3.8%) of reviewed patients had a recommended change in management, including 6 (2.9%) with target volume coverage, 1 (0.5%) with dose prescription, and 1 (0.5%) involving a fractionation schedule [11]. At the Cancer Institute in Singapore, a post-treatment audit of 118 patients demonstrated that in $5% of instances, the medical decisions regarding dose, treatment intent, or fractionation were deemed ''controversial'' or ''concerning'' [19].…”